Lemoxol (Ceftazidime Pentahydrate)

Ceftazidime inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins (PBPs) located on the inner surface of the bacterial membrane. This binding blocks the cross‑linking of peptidoglycan strands, leading to a weakened cell wall and ultimately bacterial lysis. The drug is bactericidal against many Gram‑negative organisms, including Pseudomonas aeruginosa, and retains activity against several Gram‑positive species.

The dosage of Lemoxol is individualized by the treating physician based on the type and severity of infection, the patient’s renal function, and other clinical factors. The prescriber determines the amount, frequency, and duration of intravenous or intramuscular administration, and adjustments may be required for patients with impaired kidney function.

Safety data for ceftazidime in pregnancy are limited, and the drug is classified as pregnancy category unknown. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus. Ceftazidime is excreted in breast milk in small amounts; breastfeeding decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the Lemoxol product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details—including cold‑chain handling if needed—and assists with any required import documentation.

Compared with earlier‑generation cephalosporins, ceftazidime offers broader coverage against Gram‑negative organisms, especially Pseudomonas aeruginosa, and retains activity against many β‑lactamase‑producing strains. However, it has less activity against certain Gram‑positive bacteria than first‑generation agents. Clinicians often select Lemoxol when a high‑potency, anti‑Pseudomonal option is required, balancing efficacy with the drug’s safety profile.

Lemoxol should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The product should remain in its original packaging until reconstitution. Once reconstituted, the solution should be used within the time frame specified in the label and kept at controlled room temperature if not administered immediately.

Lemoxol is supplied as a sterile powder for reconstitution and is administered by intravenous infusion or intramuscular injection. The reconstituted solution is typically diluted in an appropriate compatible fluid and infused over a period recommended by the prescriber, usually 30 minutes to 1 hour for IV use. Intramuscular dosing follows standard injection techniques.

The most serious adverse reactions to ceftazidime include severe hypersensitivity reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, neutropenia, thrombocytopenia, and, rarely, seizures, especially in patients with renal impairment or receiving high doses. Prompt recognition and discontinuation of the drug are essential if any of these events occur.

Lemoxol is contraindicated in patients with a known hypersensitivity to ceftazidime, other cephalosporins, or any component of the formulation. Caution is also advised for individuals with a history of severe allergic reactions to β‑lactam antibiotics. Patients with significant renal dysfunction may require dose adjustments, and the drug should be avoided or used only under close supervision in such cases.